Phase 3 Data: Bimekizumab Earns High Marks in HS
Bimekizumab-bkzx (Bimzelx, UCB) consistently showed sustained improvements in clinical and patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa (HS), according to results from the Phase 3 BE HEARD I and BE HEARD II trials. Bimekizumab-bkzx is an interleukin (IL)-17A and IL-17F inhibitor. The findings, which are published in the Lancet, support global regulatory submissions […]